FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Abstract Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Françoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Géraldine Gebhart
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0d02b04773dd46e4a2043969e5d6a963
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d02b04773dd46e4a2043969e5d6a963
record_format	dspace
spelling	oai:doaj.org-article:0d02b04773dd46e4a2043969e5d6a9632021-12-02T15:15:23ZFDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer10.1038/s41523-021-00331-82374-4677https://doaj.org/article/0d02b04773dd46e4a2043969e5d6a9632021-09-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00331-8https://doaj.org/toc/2374-4677Abstract Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 14 days of exemestane-everolimus (EXE-EVE) to identify MBC patients who will not benefit. The metabolic non-response rate was 66.6%. Median PFS in non-responding patients (using as cut-off 25% for SUVmax decrease) was 3.1 months compared to 6.0 months in those showing response (HR: 0.77, 95% CI: 0.40–1.50, p = 0.44). The difference was significant when using a “post-hoc” cut-off of 15% (PFS 2.2 months vs 6.4 months). ctDNA detection at D14 was associated with PFS: 2.1 months vs 5.0 months (HR-2.5, 95% CI: 1.3–5.0, p = 0.012). Detection of ctDNA and/or the absence of 18F-FDG-PET/CT response after 14 days of EXE-EVE identifies patients with a low probability of benefiting from treatment. Independent validation is needed.Andrea GombosDavid VenetLieveke AmeyePeter VuylstekePatrick NevenVincent RichardFrancois P. DuhouxJean-Francois LaesFrançoise RotheChristos SotiriouMarianne PaesmansAhmad AwadaThomas GuiotPatrick FlamenMartine Piccart-GebhartMichail IgnatiadisGéraldine GebhartNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Andrea Gombos David Venet Lieveke Ameye Peter Vuylsteke Patrick Neven Vincent Richard Francois P. Duhoux Jean-Francois Laes Françoise Rothe Christos Sotiriou Marianne Paesmans Ahmad Awada Thomas Guiot Patrick Flamen Martine Piccart-Gebhart Michail Ignatiadis Géraldine Gebhart FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
description	Abstract Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 14 days of exemestane-everolimus (EXE-EVE) to identify MBC patients who will not benefit. The metabolic non-response rate was 66.6%. Median PFS in non-responding patients (using as cut-off 25% for SUVmax decrease) was 3.1 months compared to 6.0 months in those showing response (HR: 0.77, 95% CI: 0.40–1.50, p = 0.44). The difference was significant when using a “post-hoc” cut-off of 15% (PFS 2.2 months vs 6.4 months). ctDNA detection at D14 was associated with PFS: 2.1 months vs 5.0 months (HR-2.5, 95% CI: 1.3–5.0, p = 0.012). Detection of ctDNA and/or the absence of 18F-FDG-PET/CT response after 14 days of EXE-EVE identifies patients with a low probability of benefiting from treatment. Independent validation is needed.
format	article
author	Andrea Gombos David Venet Lieveke Ameye Peter Vuylsteke Patrick Neven Vincent Richard Francois P. Duhoux Jean-Francois Laes Françoise Rothe Christos Sotiriou Marianne Paesmans Ahmad Awada Thomas Guiot Patrick Flamen Martine Piccart-Gebhart Michail Ignatiadis Géraldine Gebhart
author_facet	Andrea Gombos David Venet Lieveke Ameye Peter Vuylsteke Patrick Neven Vincent Richard Francois P. Duhoux Jean-Francois Laes Françoise Rothe Christos Sotiriou Marianne Paesmans Ahmad Awada Thomas Guiot Patrick Flamen Martine Piccart-Gebhart Michail Ignatiadis Géraldine Gebhart
author_sort	Andrea Gombos
title	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
title_short	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
title_full	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
title_fullStr	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
title_full_unstemmed	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
title_sort	fdg positron emission tomography imaging and ctdna detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0d02b04773dd46e4a2043969e5d6a963
work_keys_str_mv	AT andreagombos fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT davidvenet fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT lievekeameye fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT petervuylsteke fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT patrickneven fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT vincentrichard fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT francoispduhoux fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT jeanfrancoislaes fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT francoiserothe fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT christossotiriou fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT mariannepaesmans fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT ahmadawada fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT thomasguiot fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT patrickflamen fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT martinepiccartgebhart fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT michailignatiadis fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer AT geraldinegebhart fdgpositronemissiontomographyimagingandctdnadetectionasanearlydynamicbiomarkerofeverolimusefficacyinadvancedluminalbreastcancer
_version_	1718387490159591424

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Ejemplares similares